Robert McCormack's Biography

Robert McCormack, Head, Technology Innovation and Strategy, Veridex LLC/Johnson & Johnson

Dr. Robert McCormack is the Head of Technology Innovation and Strategy, at Veridex, A Johnson & Johnson Company. He has a vast knowledge of Circulating Tumor Cell (CTC) technology and how physicians use it to monitor therapy.

Circulating Tumor Cells: Informing and Facilitating Development and Clinical Decisions

Tuesday, 25 March 2014 at 09:00

Add to Calendar ▼2014-03-25 09:00:002014-03-25 10:00:00Europe/LondonCirculating Tumor Cells: Informing and Facilitating Development and Clinical DecisionsCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com

Circulating tumor cells (CTCs) have been detected in the blood of patients with most types of cancers. In all instances, elevated CTC numbers implies failure of the patient’s current therapy and portends a poor prognosis. These validated findings and others have been translated into the basis for incorporating CTCs in both drug discovery and patient management. This presentation will follow an algorithm to use CTCs to determine therapy effectiveness, elucidating underlying mechanisms for therapy failure, and identifying therapeutic options for patients.

Add to Calendar ▼2014-03-24 00:00:002014-03-25 00:00:00Europe/LondonCirculating Biomarkers 2014Circulating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors